Day One Biopharmaceuticals, Inc. entered into an Exclusive License Agreement with Ipsen Pharma SAS to license the right to commercialize tovorafenib outside the United States, with Ipsen paying an upfront license fee of approximately $71 million and purchasing $40 million worth of the Company's common stock.